<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10390000</article-id><article-id pub-id-type="pmc">2362989</article-id><article-id pub-id-type="pii">6690506</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vinholes</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Coleman</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lacombe</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rose</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tubiana-Hulin</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bastit</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wildiers</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Michel</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nortier</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mignolet</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ford</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><aff id="aff1">EORTC (European Organization for Research and Treatment of Cancer), Breast Cancer Cooperative Group, Brussels, Belgium</aff><aff id="aff2">EORTC Data Center, Brussels, Belgium</aff><aff id="aff3">Novartis, Basel, Switzerland</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>1999</year></pub-date><volume>80</volume><issue>1-2</issue><fpage>221</fpage><lpage>228</lpage><history><date date-type="received"><day>09</day><month>01</month><year>1998</year></date><date date-type="accepted"><day>22</day><month>10</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response to treatment. Thirty-seven patients with newly diagnosed bone metastases from breast cancer, randomized to receive oral pamidronate or placebo tablets in addition to anticancer treatment within the context of a multicentre EORTC trial, who were both assessable for radiographic response in bone and had serum and urine samples collected for more than 1 month were studied. The markers of bone metabolism measured included urinary calcium (uCa), hydroxyproline (hyp), the N-telopeptide cross-links of type I collagen (NTx) and total alkaline phosphatase. The tumour markers measured were CA15-3 and cancer-associated serum antigen (CASA). Before treatment, levels of Ntx, uCa and Hyp were elevated in 41&#x00025;, 24&#x00025; and 28&#x00025; respectively, and CA15-3 and CASA increased in 69&#x00025; and 50&#x00025;. For assessment of response and identification of progression, Ntx was the most useful bone marker. All markers behaved similarly in no change (NC) and partial response (PR) patients. There was a significant difference (<italic>P</italic> &#x02264; 0.05) in Ntx levels (compared to baseline) at 1 and 4 months and in CA15-3/CASA at 4 months between patients with PR or NC and those with progressive disease (PD), and at 4 months between those with time to progression (TP) &#x0003e; 7 and those with TP &#x02264; 7 months. The diagnostic efficiency (DE) for prediction of PD following a &#x0003e; 50&#x00025; increase in Ntx or CA15-3 was 78&#x00025; and 62&#x00025; respectively. An algorithm to predict response to therapy has been developed for future prospective evaluation. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>bone metastases</kwd><kwd>assessment of response</kwd><kwd>breast cancer</kwd><kwd>bone resorption markers</kwd><kwd>tumour markers</kwd></kwd-group></article-meta></front></article>